Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 12Glioblastoma 6Insulinoma 4Hypoglycemia 4Congenital Hyperinsulinism 4Brain Neoplasms 4Neuroendocrine Tumors 3Neuroblastoma 3Hyperinsulinism 3Recurrence 2Pheochromocytoma 2Parkinson Disease 2Oligodendroglioma 2Gliosarcoma 2Ependymoma 2Carcinoid Tumor 2Astrocytoma 2Thyroid cancer, medullary 1Sarcoma 1Parkinsonian Disorders 1Parathyroid Neoplasms 1Paraganglioma 1Optic Nerve Glioma 1Neoplasms, Neuroepithelial 1Neoplasms 1Multiple Endocrine Neoplasia 1Lewy Body Disease 1Infant, Newborn, Diseases 1Hyperparathyroidism 1Hypercalcemia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × fluorodopa F 18 × Clear all
NCT07542158 2026-04-21

Ultralow Dose PET Imaging of 18F-FDOPA

Nuclear Imaging Institute

Phase 2 Enrolling by invitation
200 enrolled
CNS

Glioma, Neoplasms, Parkinsonian Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡